Synapse - Terence Purdon

Results (61)

Discovery proteomics for analytes to predict cytokine release syndrome on day of infusion of chimeric antigen receptor (CAR) T cells

Meeting Abstract

Lakkaraja, M.; Hosszu, K.; Mcavoy, D.; Mauguen, A.; Purdon, T. J.; Auchincloss, T.; Klein, E.; Khakoo, Y.; Santomasso, B.; Senechal, B.; more...
Cytotherapy (2022)

Fulltext@MSK | Save

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
Blood (2021)

Fulltext@MSK | Save

Decreased neuroprotective analytes on day of infusion of chimeric antigen receptor (CAR) T cells are associated with neurotoxicity

Meeting Abstract

Lakkaraja, M.; Hosszu, K.; McAvoy, D.; Mauguen, A.; Purdon, T. J.; Khakoo, Y.; Santomasso, B. D.; Riviere, I.; Sadelain, M.; Curran, K. J.; more...
Bone Marrow Transplantation (2021)

Fulltext@MSK | Save

Predictors for neurotoxicity on day of infusion of chimeric antigen receptor (CAR) T cells using discovery proteomics platform

Meeting Abstract

Lakkaraja, M.; Hosszu, K.; McAvoy, D.; Mauguen, A.; Purdon, T. J.; Auchincloss, T.; Klein, E.; Khakoo, Y.; Santomasso, B.; Senechal, B.; more...
Cytotherapy (2021)

Fulltext@MSK | Save

Bispecific T-cell engaging antibodies against MUC16 demonstrate efficacy against ovarian cancer in monotherapy and in combination with PD-1 and VEGF inhibition

Journal Article

Yeku, O. O.; Rao, T. D.; Laster, I.; Kononenko, A.; Purdon, T. J.; Wang, P.; Cui, Z.; Liu, H.; Brentjens, R. J.; Spriggs, D.
Frontiers in Immunology (2021)

Fulltext@MSK | Save

Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response

Journal Article

Li, X.; Daniyan, A. F.; Lopez, A. V.; Purdon, T. J.; Brentjens, R. J.
Leukemia (2021)

Fulltext@MSK | Save

Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape– Driven relapse in multiple myeloma